0 268

Cited 37 times in

Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment

Authors
 Jun Hyung Kim  ;  Mi Na Kim  ;  Kwang-Hyub Han  ;  Seung Up Kim 
Citation
 LIVER INTERNATIONAL, Vol.35(4) : 1103-1115, 2015 
Journal Title
 LIVER INTERNATIONAL 
ISSN
 1478-3223 
Issue Date
2015
MeSH
Antiviral Agents/therapeutic use* ; Biopsy ; Elasticity ; Elasticity Imaging Techniques/methods* ; Hepatitis B, Chronic/complications ; Hepatitis B, Chronic/diagnosis* ; Hepatitis B, Chronic/drug therapy ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/diagnosis* ; Hepatitis C, Chronic/drug therapy ; Humans ; Liver/drug effects ; Liver/pathology* ; Liver Cirrhosis/diagnosis* ; Liver Cirrhosis/drug therapy ; Liver Cirrhosis/virology ; Predictive Value of Tests ; Severity of Illness Index ; Treatment Outcome
Keywords
antiviral treatment ; chronic hepatitis B ; chronic hepatitis C ; fibroscan ; hepatitis B virus ; hepatitis C virus ; liver stiffness ; transient elastography
Abstract
Accurate evaluation of the degree of liver fibrosis in patients with chronic liver diseases (CLD) is crucial, as liver fibrosis is important in determining the prognosis of liver diseases. Currently, liver biopsy (LB) is considered the gold standard for staging liver fibrosis or cirrhosis. However, utilization of LB in clinical practice is often limited because of its invasive nature, sampling error and interobserver variability. Recently, transient elastography (TE) was introduced as a noninvasive, highly reproducible technique for assessing the degree of liver fibrosis. After extensive studies, TE is now regarded as a reliable surrogate marker for grading the severity of liver fibrosis in patients with CLD. In the past few years, the role of TE in monitoring liver stiffness and determining prognosis in patients with chronic hepatitis B (CHB) or chronic hepatitis C (CHC) who are undergoing antiviral treatment has been investigated. In patients with CHB, liver stiffness values decrease with antiviral treatment. TE can also be used to predict the incidence of liver-related events during antiviral treatment. In patients with CHC, TE can be used to monitor potential regression of liver fibrosis after antiviral treatment and may predict the treatment outcome of CHC. In addition, TE is an adjunct tool for distinguishing inactive hepatitis B virus carriers from patients with chronic active hepatitis. This review article discusses the important findings from recent studies focusing on the clinical application of TE in patients with chronic viral hepatitis who are undergoing antiviral treatments.
Full Text
http://onlinelibrary.wiley.com/doi/10.1111/liv.12628/abstract
DOI
10.1111/liv.12628
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Mi Na(김미나)
Kim, Seung Up(김승업) ORCID logo https://orcid.org/0000-0002-9658-8050
Kim, Joon Hyung(김준형)
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/139884
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links